SANTA CLARA, Calif., May 2, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, today announced its selection for the prestigious NYC Bright Lights Conference at the Le Parker Meridien Hotel in New York City. Bright Lights is the only conference of its kind with an exclusive focus on publicly traded companies with disruptive and market changing intellectual property (IP). NewCardio will present on May 10, 2011 at 9 a.m. ET.
NewCardio was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property (IP). It is one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business intelligence platform.
Christopher Marlett, CEO at MDB Capital Group, comments, "It's a rare and exciting opportunity to have so many key players that are driving IP asset monetization together under one roof and we look forward to sharing NewCardio's cardiac diagnostic technology with other innovators and investors at the Bright Lights conference."
Bright Lights also features high-profile speakers including the top IP experts in the nation, such as David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO), who will be joining as a keynote speaker; in addition to Marshall Phelps, former head of Microsoft IP, and John Cronin, former head of IBM's Patent Factory, and Paul Ryan of Acacia Research.
The second annual Bright Lights Conference will take place on May 10 - 11th at the Le Parker Meridien Hotel in New York City. To learn more about the event, please visit: http://www.mdb.com.
Investors and other interested parties may access an audio only webcast of the live presentation at http://www.wsw.com/webcast/mdb2/nwci.ob/. This webcast will be archived for 90 days following the live presentation.
About MDB Capital Group
MDB Capital Group, LLC is an institutional research and investment banking firm focusing exclusively on small and micro-cap companies possessing market changing, disruptive intellectual property. For more information on MDB Capital Group, visit: http://www.mdb.com
PatenVest® is a proprietary intellectual property (IP) business intelligence platform developed by MDB Capital Group. PatentVest quantifies the appropriate valuation of IP and enables the emergence of IP as an investible asset class. For more information on PatentVest please visit: http://www.patentvest.com
Past performance is not a guarantee of future results. MDB Capital Group, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this press release. For important disclosure information regarding the covered companies in this press release, please contact: The Director of Research at (310) 526-5000 or write to: MDB Capital Group, LLC, Attention: Director of Research, 401 Wilshire Blvd., Suite 1020, Santa Monica, CA 90401.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12L ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2010 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Jeff Stanlis, Partner
SOURCE NewCardio, Inc.